Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6981118 | 0.89 | HPGD (0.61) | HTR1AADRA1A | |
| SCHEMBL6981877 | 0.88 | HTR1A (0.62) | HTR1AADRA1A | |
| Methane SCHEMBL7459255 | 0.84 | HTR1A (0.57) | HTR1AADRA1A | |
| SCHEMBL19971721 | 0.83 | HTR1A (0.58) | HTR1AADRA1A | |
| SCHEMBL7466895 | 0.82 | HTR1A (0.57) | HTR1AADRA1A | |
| SCHEMBL3904865 | 0.81 | HTR1A (0.51) | HTR1AADRA1A | |
| SCHEMBL4021078 | 0.81 | HTR1A (0.53) | HTR1AADRA1A | |
| SCHEMBL6984019 | 0.81 | HTR1A (0.59) | HTR1AADRA1A | |
| SCHEMBL6985467 | 0.80 | HTR1A (0.55) | HTR1AADRA1A | |
| SCHEMBL2075037 | 0.80 | HPGD (0.68) | HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180079742-A1 | Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds | AUSPEX PHARMACEUTICALS, INC. | 2018-03-22 | — | — | US | disclosed |
| EP-0946546-B1 | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE | PF MEDICAMENT (FR) | 2003-06-25 | — | — | EP | disclosed |
| CN-1098263-C | Pyridin-2-yl-methylamine derivatives, method of preparing and application as medicine | PF MEDICAMENT (FR) | 2003-01-08 | — | — | CN | disclosed |
| EP-1119564-B1 | ARYL- 4-FLUORO-4- (2-PYRIDIN-2-YL-ETHYLAMINO)-METHYL]-PIPERIDIN-1-YL -METHANONE DERIVATIVES AS 5-HT1 RECEPTOR ANTAGONISTS | PF MEDICAMENT (FR) | 2002-12-18 | — | — | EP | disclosed |
| US-6448268-B1 | TREATING PATHOLOGIES INVOLVING SEROTONINERGIC DYSFUNCTION, IN PARTICULAR ANXIETY, DEPRESSION, NEURODEGENERATION AND THE PERCEPTION OF PAIN; SELECTIVITY; SIDE EFFECT REDUCTION | PIERRE FABRE MEDICAMENT (FR) | 2002-09-10 | — | — | US | disclosed |
| EP-1119564-A1 | ARYL- 4-FLUORO-4- (2-PYRIDIN-2-YL-ETHYLAMINO)-METHYL]-PIPERIDIN-1-YL -METHANONE DERIVATIVES AS 5-HT1 RECEPTOR ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000021953-A1 | ARYL-{4-FLUORO-4-[(2-PYRIDIN-2-YL-ETHYLAMINO)-METHYL]-PIPERIDIN-1-YL}-METHANONE DERIVATIVES AS 5-HT1 RECEPTOR ANTAGONISTS | PIERRE FABRE MEDICAMENT (FR) | 2000-04-20 | — | — | WO | disclosed |
| US-6020345-A | Pyridin-2-yl-methylamine derivatives, method of preparing and application as medicine | PIERRE FABRE MEDICAMENT (FR) | 2000-02-01 | — | — | US | disclosed |
| CN-1242772-A | Pyridin-2-yl-methylamine derivatives, method of preparing and application as medicine | PF MEDICAMENT (FR) | 2000-01-26 | — | — | CN | disclosed |
| EP-0946546-A1 | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE | PIERRE FABRE MEDICAMENT (FR) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998022459-A1 | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE | PIERRE FABRE MEDICAMENT (FR) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079742-A1 | Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds | HTR2C, HTR5A, HTR1A | HTR1A 3/4885ADRA1A 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.